TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in pain during intercourse
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in global sexual function
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Dietary sulfur amino acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in gut microbial communities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in pain and pain interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in meaning in life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Infant brain injury assessed using the Kidokoro injury scoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total and regional infant brain volumes assessed using MANTiS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diffusion tensor imaging measures of fractional anisotropy (FA), mean (MD), radial (RD), and axial (AD) diffusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ottawa Bowel Preparation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reduction of lymphorrhea rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Urine Samples Positive for Naltrexone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Experiencing 3 or More Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Appropriate VTE prophylaxis
Endpoint domain: Adverse events/effects
Primary endpoint: Level of glycosylated haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complications during entry in laparoscopy
Endpoint domain: Adverse events/effects
Primary endpoint: Success Rate of Minimal Sedation Colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of patients reaching Assessment in Ankylosing Spondylitis 20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Anxiety Disorder-7 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the plasma concentration-time curve (AUC(INF))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of surgical interference
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement proportion of pulmonary fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of treated Patients by practice within study period
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Point prevalence smoking abstinence of treated patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of Vibrational Spectroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in measurement of mTOR activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Percentage of RT-qPCR Confirmed Symptomatic Dengue Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic value of serum NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of cells expressing CD45
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of retinopathy of prematurity (ROP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: Closure Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients with fever prescribed artemether-lumefantrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insertion depth of nasopharyngeal probe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PACT-Q2 Scores at Second Assessment Compared to Baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean PACT-Q2 Scores at Last Assessment Compared to Baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean PACT-Q2 Scores Compared Between Treatment Groups at Second Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean PACT-Q2 Scores Compared Between Treatment Groups at Last Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of intraoperative awareness
Endpoint domain: Adverse events/effects
Primary endpoint: Relapse Incidence
Endpoint domain: Mortality/survival
Primary endpoint: Non Relapse Mortality (NRM) Incidence
Endpoint domain: Mortality/survival
Primary endpoint: Heat tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of alcohol-related cognitive disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bone signal changes detected by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of the eardrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar, pelvic, and lumbopelvic motions after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamstrings muscle length after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of clinical deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in spontaneous pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side-effects due to immunotherapy treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients in major molecular response (MMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total insulin infused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diaphragm muscle effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of canagliflozin and major metabolites in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy measured by RECIST 1.1 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy measured by modified RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Taken for Endotracheal Tube Placement Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants in Which the Tube Was Successfully Positioned at First Attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of related major adverse events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy - Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophil characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to return to bowel function at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: BCDVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Days to Neutrophil Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Days to Platelet Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Radiographic Recurrence at 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: 1-year adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Initial subcutaneous interstitial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Febrile neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Treatment-related hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Pharmacokinetics of bemiparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Successful closure of patent ductus arteriosus without complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving DAS28<3.2 or maintaining a change in DAS from baseline of ≥ 1.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival Rate of the Implant
Endpoint domain: Mortality/survival
Primary endpoint: Changes in clinical management
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Limb Symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer Detection Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Expression of P53 induced genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From 0 to Infinity [AUC(0-∞)] of Baricitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding habits
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Difference between SpHb and SaHb values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in % Liver Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Quality of life score at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Level of participation
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Progesterone serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lipid fractions (HDL, LDL, total cholesterol, triglycerides)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global Brain Glucose PET Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brain MR Volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Resistance (HOMA2-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in pupil size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in PTSD Checklist for DSM-5 (PCL-5) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to discharge alive from hospital
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility of recruitment and follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Count of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum levels of Hemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnosis of obstetric anal sphincter injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Basic Life Support Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recipient- and donor-site complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mania symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participants' attendance to the program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overall Pathological Complete Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Grade 4 Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Extubation Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peri-implant probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lower extremity deep vein thrombosis on venous duplex ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Evidence of cardiac ischemia on the electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in number of headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of bleeding events, annualized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in CT chest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Maximum Lesional FDG Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LH/hCG receptor expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Expression and activity of proteases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of residents with documented and satisfied preferences and needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Investigator Global Assessment (IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IVUS-derived measurement of pulmonary artery wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pulmonary microvascular circulation dilator responses to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood concentration of pregabalin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hemoglobin (Hg) Level at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Composite Events of Death, Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)
Endpoint domain: Mortality/survival
Primary endpoint: cancer related deaths
Endpoint domain: Mortality/survival
Primary endpoint: local relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Change in Pittsburgh Sleep Quality Index Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence rate of clinical episodes of malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cmax for [14C]-GDC-0810
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum concentration (Tmax) for GDC-0810
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Concentration-Time Curve (AUC) from Hour 0 to Last Measurable Concentration (AUC0-t) for GDC-0810
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of TOFr<0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower-limb power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with mRS score of 2 or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure atherosclerotic plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of reactive species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non fatal re-MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: appropriate ICD discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment Success (conversion from ineligible to eligible status for lung resection)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transfer of dietary nitrogen to metabolic pools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 10 Meter Walk Test (Self-selected walking speed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operational success according to the van Overbeek classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Deglutition Handicap Index score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical manifestations of hyperplasia of mammary glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Heart rate complexity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Center of Pressure complexity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of endocrine resistant disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Oxidative stress assessment (8-OHdG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidative stress assessment (8-isoprostane)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Well-being Scale - Self-Administered (QWB-SA)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Usual dietary intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in neural response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in adherence to the behavioral weight loss program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in impulsivity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: clinical progression free survival (cPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Postnatal respiratory morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Passage of antiviral antibodies from mother to newborn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vertical transmission of RSV and/or SARS-COV2 from infected mother to the offspring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of MM36
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Observed Plasma Concentration (Tmax) of MM36
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero To the Time of Last Quantifiable Plasma Concentration of MM36
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in DAS28 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: carboxyhemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: end tidal carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sedation characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of early esophageal squamous neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Confirmed diagnosis of COVID-19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Ischemic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in ADHD Investigator Symptom Rating Scale (AISRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Discontinued Zolpidem Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Food Choice Change
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Food Tastiness Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Food Health Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in symptoms of vaginal health index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in vaginal and vulvar pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes